A Safe and Easy Introduction of Darbepoetin-Alpha in Patients Receiving Maintenance Hemodialysis and Epoetin Monotherapy: A “Half-and-Half” Combination Therapy()

BACKGROUND: In hemodialysis (HD) patients requiring anemia management, the 3-fold longer terminal half-life (25.3 hours) of darbepoetin-alpha (DA) results in reduced dose frequency when compared with recombinant human erythropoietin (EPO) -alpha or -beta by intravenous administration (8.5 hours). Ho...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimamatsu, Kazumasa, Inamasu, Hiroko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2013
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3862190/
https://www.ncbi.nlm.nih.gov/pubmed/24384988
http://dx.doi.org/10.1016/j.curtheres.2012.12.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3862190/
https://www.ncbi.nlm.nih.gov/pubmed/24384988
http://dx.doi.org/10.1016/j.curtheres.2012.12.001

Ejemplares similares